- In March 2025, Galderma will present extensive updates at the American Academy of Dermatology (AAD) Annual Meeting. The company will share new data on Nemluvio (nemolizumab), demonstrating its benefits in treating prurigo nodularis and atopic dermatitis. In addition, updates will be provided on Restylane, Sculptra, and Relfydess, highlighting advancements in aesthetic treatments, including synergistic effects and long-term efficacy. These innovations aim to improve patient outcomes, offering new solutions for sensitive skin, acne, and aging skin. The updates underscore Galderma's leadership in dermatology and its continued growth in the market
- In January 2025, Allergan Aesthetics launched its new AA Signature Program at IMCAS 2025, designed to redefine patient-centric, multimodal treatment plans. This program aims to offer personalized treatment regimens by combining advanced aesthetic solutions such as BOTOX and JUVÉDERM, with a focus on enhancing results through customized approaches. The initiative is expected to improve patient satisfaction by tailoring treatments to individual needs, addressing various aesthetic concerns, and achieving natural-looking outcomes. This program underscores Allergan's commitment to innovation and enhancing patient experience in the aesthetic field
- In March 2024, AbbVie and Allergan Aesthetics will present new data at the American Academy of Dermatology (AAD) Annual Meeting. The data includes efficacy and safety results from various treatments, such as RINVOQ (upadacitinib) for atopic dermatitis, and SKYRIZI (risankizumab-rzaa) for psoriasis. AbbVie will also introduce Phase 2 data for lutikizumab (ABT-981) in hidradenitis suppurativa. Allergan Aesthetics will highlight BOTOX Cosmetic for platysma prominence and JUVÉDERM VOLUMA XC for temple hollowing. These updates aim to advance dermatology and aesthetics, offering new treatment options and improving patient outcomes
- In January 2023, Galderma presented new data at IMCAS 2023, showcasing the effectiveness and safety of its Sculptra treatment. This injectable poly-L-lactic acid (PLLA) is FDA-approved for facial rejuvenation and helps stimulate collagen production to restore fullness and firmness in the face. The results of the Sculptra Cheek Wrinkle study demonstrated long-lasting effects with significant aesthetic improvement, enhanced patient satisfaction, and improved skin quality over a 24-month period. In addition, Galderma shared positive findings from its Alluzience (abobotulinumtoxinA) phase IV STAR study, highlighting high patient satisfaction and longer-lasting effects for treating glabellar lines. These innovations aim to provide more effective, patient-centric aesthetic treatments
